Actuate Therapeutics Inc.

Actuate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through inhibition of glycogen synthase kinase-3, particularly the GSK-3β isoform. Its lead investigational drug, elraglusib, is a small-molecule inhibitor designed to block GSK-3β function within cancer cells, targeting key signaling pathways like NF-κB that promote tumor survival, growth, migration, invasion, and resistance to chemotherapy while enhancing anti-tumor immunity. Elraglusib is under evaluation in Phase 2 trials for metastatic pancreatic ductal adenocarcinoma, with Orphan Drug and Fast Track Designations, and in Phase 1/2 trials for refractory pediatric malignancies such as Ewing sarcoma and neuroblastoma, as well as metastatic melanoma and colorectal cancer. The company also pursues an oral formulation of elraglusib, completing Phase 1 in healthy volunteers and planning further studies in advanced cancers. Actuate Therapeutics Inc. operates in the biotechnology sector, addressing unmet needs in oncology for solid tumors and hematologic malignancies. Founded in 2015 and headquartered in Fort Worth, Texas, it maintains a strategic pipeline aimed at GSK-3β associated diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Daniel M. Schmitt

Employees

12

Headquarters

Fort Worth, TX, United States

Website

actuatetherapeutics.com